医学
彭布罗利珠单抗
危险系数
内科学
贝伐单抗
人口
肿瘤科
化疗
外科
无进展生存期
中期分析
置信区间
癌症
胃肠病学
临床试验
免疫疗法
环境卫生
作者
Nicoletta Colombo,Coraline Dubot,Domenica Lorusso,M. Valeria Cáceres,Kosei Hasegawa,Ronnie Shapira‐Frommer,Krishnansu S. Tewari,Pamela Salman,Edwin Hoyos Usta,Eduardo Yañez,Mahmut Gümüş,Mivael Olivera,Vanessa Samouëlian,Vincent Castonguay,Arkhipov Alexander,Sarper Toker,Kan Li,Stephen J. O’Keefe,Bradley J. Monk
标识
DOI：10.1056/nejmoa2112435
摘要
Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)–positive metastatic or unresectable cervical cancer that has progressed during chemotherapy. We assessed the relative benefit of adding pembrolizumab to chemotherapy with or without bevacizumab.
科研通智能强力驱动
Strongly Powered by AbleSci AI
SYLH
科研小民工
劲秉
昏睡的蟠桃
cdercder
默默地读文献
nozero
back you up
pluto
山花浪漫
迷人秋烟
子车茗
121231233
iNk
迟大猫
MchemG
实验好难
pcr163
图图
彭于彦祖
皖公网安备34019202002308
